Total
0
Shares
Neuren Pharmaceuticals (ASX:NEU) gets Ethics Committee green light for upcoming clinical trial
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Chimeric Therapeutics (CHM) will progress to the second dose level of its clinical trial after confirming no dose-limiting toxicities in the first patient cohort
  • The phase one dose escalation study is assessing the safety and maximum tolerated dose of Chimeric's cell therapy, Chlorotoxin CAR T (CLTX CAR T)
  • CLTX CAR T is unique in using chlorotoxin, a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor
  • The initial patient dosing concluded in March and after completing a 28-day follow-up period, no patient has reported dose limiting toxicities.
  • The second dose level will administer the CAR T cells by two routes, intratumoral and intracranial intraventricular
  • Shares are 1.7 per cent higher trading at 30 cents each

Chimeric Therapeutics (CHM) will progress to the second dose level of its clinical trial after confirming no dose-limiting toxicities in the first patient cohort.

The phase one dose escalation study is assessing the safety and maximum tolerated dose of Chimeric's cell therapy, Chlorotoxin CAR T (CLTX CAR T), which is the first of its kind and has the potential to address unmet medical needs of patients with recurrent or progressive glioblastoma.

CLTX CAR T is unique in using chlorotoxin (CLTX), a peptide derived from scorpion toxin, as the tumour-targeting component of the chimeric antigen receptor (CAR).

The phase one study aims to enrol between 18 and 36 patients with MMP2+ recurrent or progressive glioblastoma across four dose levels.

The initial patient dosing concluded in March and after completing a 28-day follow-up period, no patient has reported experiencing dose limiting toxicities.

Consequently, the company can advance to the second dose level, which will administer the CAR T cells by two routes, intratumoral and intracranial intraventricular.

Chimeric's CEO, Jennifer Chow said the announcement is a significant milestone for the company, enabling the advancement of an important therapy for patients with progressive or recurrent glioblastoma.

The initial dosing was staggered to monitor any adverse events between dosings, however, the next stage will enable patient dosing without a mandated stagger.

The clinical trial is taking place at City of Hope, a world-renowned cancer research and treatment centre near Los Angeles.

Shares are 1.7 per cent higher trading at 30 cents each at 10:38 am AEST.

CHM by the numbers
More From The Market Herald
Creso Pharma (ASX:CPH) - Creso Pharma - The Market Herald

" Creso Pharma (ASX:CPH) completes US dual listing

Creso Pharma (CPH) is officially dual listed, after completing its listing on the US OTCQB stock exchange.
The Market Herald Video

" US regulator approves expanded use of Avita Medical’s (ASX:AVH) RECELL System

The US regulator has approved the expanded use of Avita Medical’s (AVH) RECELL system in combination with meshed autographs to treat burns patients.
Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs term sheet with Cubert

Advanced Human Imaging (AHI) has signed a binding term sheet with Toronto-based digital health provider Cubert Inc.
Microequities Asset Management (ASX:MAM) posts 140pc boost to half-yearly profit

" Patrys (ASX:PAB) receives $600k R&D tax incentive refund

Patrys (PAB), through its wholly owned Nucleus Therapeutics subsidiary, has received a research and development (R&D) tax incentive refund of $626,780 for the